Table 4.
PIK3CA mutation, HPV, and p16 status association with the overall and disease-free survival by univariable analysis.
| Overall Survival | Disease-Free Survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Median (Years) | 3-Year % (95% CI) |
HR (95%CI) | p * | Median, (Years) | 3-Year % (95% CI) |
HR (95% CI) | p * | |
| PIK3CA | ||||||||
| MUT | 6.2 | 65 (50–83) | 1 | 0.090 | NR | 77 (63–95) | 1 | 0.198 |
| WT | 4.0 | 54 (41–70) | 1.71 (0.91–3.18) | 4.8 | 72 (58–90) | 1.80 (0.73–4.42) | ||
| HPV status | ||||||||
| Positive | 5.8 | 65 (54–78) | 1 | 0.007 | NR | 83 (72–94) | 1 | 0.001 |
| Not detected | 2.4 | 36 (19–69) | 2.40 (1.15–4.61) | 2.2 | 43 (21–90) | 4.81 (1.74–13.29) | ||
| p16 overexpression | ||||||||
| No | 2.6 | 46 (33–64) | 1 | 0.089 | 4.8 | 59 (44–80) | 1 | 0.029 |
| Yes | 6.9 | 73 (60–90) | 0.58 (0.31–1.10) | NR | 91 (81–100) | 0.34 (0.13–0.94) | ||
* Log-rank test; HR = Hazard Ratio; 95% CI = 95% Confidence Interval; NR = Not Reached; MUT = mutated; Wt = wild-type.